Literature DB >> 24802096

Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience.

Tadamasa Yoshitake1, Katsumasa Nakamura, Yoshiyuki Shioyama, Tomonari Sasaki, Saiji Ohga, Makoto Shinoto, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Yoshio Matsuo, Shingo Baba, Hiroshi Honda.   

Abstract

BACKGROUND: Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation.
METHODS: Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8-40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6-91 months).
RESULTS: Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 %, respectively. Two patients (2.3 %) had Grade 2 radiation pneumonitis, and six patients (6.8 %) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater.
CONCLUSIONS: SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.

Entities:  

Mesh:

Year:  2014        PMID: 24802096     DOI: 10.1007/s10147-014-0698-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  19 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer.

Authors:  Atsuya Takeda; Etsuo Kunieda; Naoko Sanuki; Yousuke Aoki; Yohei Oku; Hiroshi Handa
Journal:  Lung Cancer       Date:  2012-01-31       Impact factor: 5.705

3.  Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship.

Authors:  Kaori Asai; Yoshiyuki Shioyama; Katsumasa Nakamura; Tomonari Sasaki; Saiji Ohga; Takeshi Nonoshita; Tadamasa Yoshitake; Kayoko Ohnishi; Kotaro Terashima; Keiji Matsumoto; Hideki Hirata; Hiroshi Honda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-23       Impact factor: 7.038

4.  Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.

Authors:  Naomi E Verstegen; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2011-11-05       Impact factor: 6.280

5.  Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group.

Authors:  Yasushi Nagata; Masahiro Hiraoka; Takashi Mizowaki; Yuichiro Narita; Yukinori Matsuo; Yoshiki Norihisa; Hiroshi Onishi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-01       Impact factor: 7.038

Review 6.  Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging.

Authors:  Jessica C Sieren; Yoshiharu Ohno; Hisanobu Koyama; Kazuro Sugimura; Geoffrey McLennan
Journal:  J Magn Reson Imaging       Date:  2010-12       Impact factor: 4.813

7.  Stereotactic radiotherapy for lung and liver tumors using a body cast system: setup accuracy and preliminary clinical outcome.

Authors:  Yoshiyuki Shioyama; Katsumasa Nakamura; Shigeo Anai; Tomonari Sasaki; Saiji Ooga; Madoka Saku; Yusuke Urashima; Tadamasa Yoshitake; Takashi Toba; Hiromi Terashima; Hiroshi Honda
Journal:  Radiat Med       Date:  2005-09

8.  A clinical evaluation of visual feedback-guided breath-hold reproducibility of tumor location.

Authors:  Tadamasa Yoshitake; Yoshiyuki Shioyama; Katsumasa Nakamura; Saiji Ohga; Takeshi Nonoshita; Kayoko Ohnishi; Kotaro Terashima; Hidetaka Arimura; Hideki Hirata; Hiroshi Honda
Journal:  Phys Med Biol       Date:  2009-11-11       Impact factor: 3.609

Review 9.  Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review.

Authors:  Angela van Baardwijk; Wolfgang A Tomé; Wouter van Elmpt; Søren M Bentzen; Bart Reymen; Rinus Wanders; Ruud Houben; Michel Ollers; Philippe Lambin; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2012-10-12       Impact factor: 6.280

10.  Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images.

Authors:  Hiroaki Nomori; Kenichi Watanabe; Takashi Ohtsuka; Tsuguo Naruke; Keiichi Suemasu; Kimiichi Uno
Journal:  Lung Cancer       Date:  2004-07       Impact factor: 5.705

View more
  6 in total

1.  Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review.

Authors:  I S Voruganti; E Donovan; C Walker-Dilks; A Swaminath
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

2.  Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer.

Authors:  Zhen Wang; Ao-Mei Li; Jie Gao; Jing Li; Bing Li; Percy Lee; Charles B Simone; Yong Song; Xi-Xu Zhu
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 3.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

4.  Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor.

Authors:  Roman O Kowalchuk; Michael R Waters; Sujith Baliga; K Martin Richardson; Kelly M Spencer; James M Larner; Charles R Kersh
Journal:  Transl Lung Cancer Res       Date:  2020-10

5.  Optimizing the prescription isodose level in stereotactic volumetric-modulated arc radiotherapy of lung lesions as a potential for dose de-escalation.

Authors:  Mark Chan; Matthew Wong; Ronnie Leung; Steven Cheung; Oliver Blanck
Journal:  Radiat Oncol       Date:  2018-02-09       Impact factor: 3.481

6.  Clinical characteristics and outcome of pneumothorax after stereotactic body radiotherapy for lung tumors.

Authors:  Kaori Asai; Katsumasa Nakamura; Yoshiyuki Shioyama; Tomonari Sasaki; Yoshio Matsuo; Saiji Ohga; Tadamasa Yoshitake; Kotaro Terashima; Makoto Shinoto; Keiji Matsumoto; Hidenari Hirata; Hiroshi Honda
Journal:  Int J Clin Oncol       Date:  2015-04-28       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.